Published
{
"ticker": "AMGN",
"cik": "0000318154",
"company": "Amgen Inc.",
"business_type": "biopharmaceutical",
"schema_template": "standard (product sales and total revenues / cost of sales / operating income / net income, plus product-level and U.S. versus rest-of-world product sales, which is how a single-segment biotechnology company is read)",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual dollars (not millions); share counts in actual shares; per-share figures in dollars",
"units_notes_seen": {
"FY2025 10-K consolidated statements of income": "(In millions, except per-share data)",
"FY2025 10-K consolidated balance sheets": "(In millions, except per-share data)",
"FY2025 10-K consolidated statements of stockholders' equity": "(In millions, except per-share data)",
"FY2025 10-K consolidated statements of cash flows": "(In millions)",
"FY2025 10-K revenues note (Note 3)": "Revenues were as follows (in millions):",
"Q2 2026 10-Q condensed consolidated statements of income": "(In millions, except per-share data)",
"Q2 2026 10-Q condensed consolidated balance sheets": "(In millions, except per-share data)",
"Q2 2026 10-Q condensed consolidated statements of stockholders' equity": "(In millions, except per-share data)",
"Q2 2026 10-Q condensed consolidated statements of cash flows": "(In millions)",
"Q2 2026 10-Q revenues note (Note 3)": "Revenues were as follows (in millions):",
"Q2 2026 earnings release, reconciliations of cash flows": "(In millions)",
"Fourth-quarter 2025 earnings release, reconciliations of cash flows": "(In millions)"
},
"adjustments": {
"splits_applied": [],
"adr_ratio": null,
"fx": "none; Amgen reports in U.S. dollars"
},
"annual": [
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2025-01-01",
"period_end": "2025-12-31",
"period_type": "fiscal year",
"source_accession": "0000318154-26-000010",
"income_statement": {
"product_sales": 35148000000,
"other_revenues": 1603000000,
"total_revenues": 36751000000,
"cost_of_sales": 12037000000,
"research_and_development": 7272000000,
"selling_general_and_administrative": 7050000000,
"other_operating_expenses": 1312000000,
"total_operating_expenses": 27671000000,
"operating_income": 9080000000,
"interest_expense_net": -2755000000,
"other_income_expense_net": 2651000000,
"income_before_income_taxes": 8976000000,
"provision_for_income_taxes": 1265000000,
"net_income": 7711000000,
"basic_eps": 14.33,
"diluted_eps": 14.23,
"basic_shares": 538000000,
"diluted_shares": 542000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 9129000000,
"trade_receivables_net": 9570000000,
"inventories": 6225000000,
"other_current_assets": 4133000000,
"total_current_assets": 29057000000,
"property_plant_and_equipment_net": 7913000000,
"intangible_assets_net": 22276000000,
"goodwill": 18680000000,
"other_noncurrent_assets": 12660000000,
"total_assets": 90586000000,
"accounts_payable": 2367000000,
"accrued_liabilities": 18523000000,
"current_portion_of_long_term_debt": 4599000000,
"total_current_liabilities": 25489000000,
"long_term_debt": 50005000000,
"long_term_deferred_tax_liabilities": 1366000000,
"long_term_tax_liabilities": 2690000000,
"other_noncurrent_liabilities": 2378000000,
"common_stock_and_additional_paid_in_capital": 34023000000,
"accumulated_deficit": -25107000000,
"accumulated_other_comprehensive_loss": -258000000,
"total_stockholders_equity": 8658000000,
"total_liabilities_and_stockholders_equity": 90586000000,
"shares_outstanding": 538800000,
"total_debt_derived": 54604000000,
"total_liabilities_derived": 81928000000
},
"cash_flow": {
"depreciation_amortization_and_other": 5167000000,
"impairment_of_intangible_assets": 1200000000,
"stock_based_compensation": 494000000,
"operating_cash_flow": 9958000000,
"cash_paid_for_acquisitions": -53000000,
"capex": -1858000000,
"investing_cash_flow": -1943000000,
"net_proceeds_from_issuance_of_debt": 0,
"extinguishment_of_debt": -683000000,
"repayment_of_debt": -5000000000,
"repurchases_of_common_stock": 0,
"dividends_paid": -5124000000,
"financing_cash_flow": -10859000000,
"free_cash_flow": 8100000000
},
"product_sales_by_product": {
"prolia": 4414000000,
"repatha": 3016000000,
"otezla": 2265000000,
"enbrel": 2226000000,
"evenity": 2100000000,
"xgeva": 2084000000,
"tepezza": 1903000000,
"blincyto": 1559000000,
"nplate": 1524000000,
"tezspire": 1478000000,
"kyprolis": 1412000000,
"aranesp": 1389000000,
"krystexxa": 1340000000,
"vectibix": 1175000000,
"other_products": 7263000000,
"total_product_sales": 35148000000
},
"product_sales_by_geography": {
"united_states": 25656000000,
"rest_of_world": 9492000000
},
"dividends": {
"dividends_declared": 5228000000,
"dividends_declared_per_share": 9.66
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2024-01-01",
"period_end": "2024-12-31",
"period_type": "fiscal year",
"source_accession": "0000318154-26-000010",
"income_statement": {
"product_sales": 32026000000,
"other_revenues": 1398000000,
"total_revenues": 33424000000,
"cost_of_sales": 12858000000,
"research_and_development": 5964000000,
"selling_general_and_administrative": 7096000000,
"other_operating_expenses": 248000000,
"total_operating_expenses": 26166000000,
"operating_income": 7258000000,
"interest_expense_net": -3155000000,
"other_income_expense_net": 506000000,
"income_before_income_taxes": 4609000000,
"provision_for_income_taxes": 519000000,
"net_income": 4090000000,
"basic_eps": 7.62,
"diluted_eps": 7.56,
"basic_shares": 537000000,
"diluted_shares": 541000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 11973000000,
"trade_receivables_net": 6782000000,
"inventories": 6998000000,
"other_current_assets": 3277000000,
"total_current_assets": 29030000000,
"property_plant_and_equipment_net": 6543000000,
"intangible_assets_net": 27699000000,
"goodwill": 18637000000,
"other_noncurrent_assets": 9930000000,
"total_assets": 91839000000,
"accounts_payable": 1908000000,
"accrued_liabilities": 17641000000,
"current_portion_of_long_term_debt": 3550000000,
"total_current_liabilities": 23099000000,
"long_term_debt": 56549000000,
"long_term_deferred_tax_liabilities": 1616000000,
"long_term_tax_liabilities": 2349000000,
"other_noncurrent_liabilities": 2349000000,
"common_stock_and_additional_paid_in_capital": 33533000000,
"accumulated_deficit": -27590000000,
"accumulated_other_comprehensive_loss": -66000000,
"total_stockholders_equity": 5877000000,
"total_liabilities_and_stockholders_equity": 91839000000,
"shares_outstanding": 536900000,
"total_debt_derived": 60099000000,
"total_liabilities_derived": 85962000000
},
"cash_flow": {
"depreciation_amortization_and_other": 5592000000,
"impairment_of_intangible_assets": 159000000,
"stock_based_compensation": 530000000,
"operating_cash_flow": 11490000000,
"cash_paid_for_acquisitions": 0,
"capex": -1096000000,
"investing_cash_flow": -1046000000,
"net_proceeds_from_issuance_of_debt": 0,
"extinguishment_of_debt": -659000000,
"repayment_of_debt": -3600000000,
"repurchases_of_common_stock": -200000000,
"dividends_paid": -4832000000,
"financing_cash_flow": -9415000000,
"free_cash_flow": 10394000000
},
"product_sales_by_product": {
"prolia": 4374000000,
"repatha": 2222000000,
"otezla": 2126000000,
"enbrel": 3316000000,
"evenity": 1563000000,
"xgeva": 2225000000,
"tepezza": 1851000000,
"blincyto": 1216000000,
"nplate": 1456000000,
"tezspire": 972000000,
"kyprolis": 1503000000,
"aranesp": 1342000000,
"krystexxa": 1185000000,
"vectibix": 1045000000,
"other_products": 5630000000,
"total_product_sales": 32026000000
},
"product_sales_by_geography": {
"united_states": 23301000000,
"rest_of_world": 8725000000
},
"dividends": {
"dividends_declared": 4931000000,
"dividends_declared_per_share": 9.13
}
},
{
"fiscal_year": 2023,
"label": "FY2023",
"period_start": "2023-01-01",
"period_end": "2023-12-31",
"period_type": "fiscal year",
"source_accession": "0000318154-26-000010",
"income_statement": {
"product_sales": 26910000000,
"other_revenues": 1280000000,
"total_revenues": 28190000000,
"cost_of_sales": 8451000000,
"research_and_development": 4784000000,
"selling_general_and_administrative": 6179000000,
"other_operating_expenses": 879000000,
"total_operating_expenses": 20293000000,
"operating_income": 7897000000,
"interest_expense_net": -2875000000,
"other_income_expense_net": 2833000000,
"income_before_income_taxes": 7855000000,
"provision_for_income_taxes": 1138000000,
"net_income": 6717000000,
"basic_eps": 12.56,
"diluted_eps": 12.49,
"basic_shares": 535000000,
"diluted_shares": 538000000
},
"cash_flow": {
"depreciation_amortization_and_other": 4071000000,
"impairment_of_intangible_assets": 851000000,
"stock_based_compensation": 431000000,
"operating_cash_flow": 8471000000,
"cash_paid_for_acquisitions": -26989000000,
"capex": -1112000000,
"investing_cash_flow": -26204000000,
"net_proceeds_from_issuance_of_debt": 27777000000,
"extinguishment_of_debt": -647000000,
"repayment_of_debt": -1454000000,
"repurchases_of_common_stock": 0,
"dividends_paid": -4556000000,
"financing_cash_flow": 21048000000,
"free_cash_flow": 7359000000
},
"product_sales_by_product": {
"prolia": 4048000000,
"repatha": 1635000000,
"otezla": 2188000000,
"enbrel": 3697000000,
"evenity": 1160000000,
"xgeva": 2112000000,
"tepezza": 448000000,
"blincyto": 861000000,
"nplate": 1477000000,
"tezspire": 567000000,
"kyprolis": 1403000000,
"aranesp": 1362000000,
"krystexxa": 272000000,
"vectibix": 984000000,
"other_products": 4696000000,
"total_product_sales": 26910000000
},
"product_sales_by_geography": {
"united_states": 19272000000,
"rest_of_world": 7638000000
},
"dividends": {
"dividends_declared": 4644000000,
"dividends_declared_per_share": 8.64
}
}
],
"quarterly": [
{
"fiscal_year": 2026,
"fiscal_quarter": 2,
"label": "Q2 2026",
"period_start": "2026-04-01",
"period_end": "2026-06-30",
"period_type": "three months",
"source_accession": "0000318154-26-000126",
"cash_flow_source_accession": "0000318154-26-000124",
"income_statement": {
"product_sales": 9537000000,
"other_revenues": 517000000,
"total_revenues": 10054000000,
"cost_of_sales": 2811000000,
"research_and_development": 1868000000,
"selling_general_and_administrative": 1745000000,
"other_operating_expenses": 116000000,
"total_operating_expenses": 6540000000,
"operating_income": 3514000000,
"interest_expense_net": -673000000,
"other_income_expense_net": -73000000,
"income_before_income_taxes": 2768000000,
"provision_for_income_taxes": 393000000,
"net_income": 2375000000,
"basic_eps": 4.4,
"diluted_eps": 4.37,
"basic_shares": 540000000,
"diluted_shares": 544000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 13989000000,
"trade_receivables_net": 10227000000,
"inventories": 6220000000,
"other_current_assets": 4525000000,
"total_current_assets": 34961000000,
"property_plant_and_equipment_net": 8547000000,
"intangible_assets_net": 20487000000,
"goodwill": 18668000000,
"other_noncurrent_assets": 12976000000,
"total_assets": 95639000000,
"accounts_payable": 2865000000,
"accrued_liabilities": 17192000000,
"current_portion_of_long_term_debt": 5445000000,
"total_current_liabilities": 25502000000,
"long_term_debt": 51859000000,
"long_term_deferred_tax_liabilities": 1301000000,
"long_term_tax_liabilities": 2844000000,
"other_noncurrent_liabilities": 2445000000,
"common_stock_and_additional_paid_in_capital": 34082000000,
"accumulated_deficit": -22275000000,
"accumulated_other_comprehensive_loss": -119000000,
"total_stockholders_equity": 11688000000,
"total_liabilities_and_stockholders_equity": 95639000000,
"shares_outstanding": 540600000,
"total_debt_derived": 57304000000,
"total_liabilities_derived": 83951000000
},
"cash_flow": {
"operating_cash_flow": 4002000000,
"investing_cash_flow": -569000000,
"financing_cash_flow": -1482000000,
"capex": -513000000,
"free_cash_flow": 3489000000
},
"product_sales_by_product": {
"repatha": 953000000,
"prolia": 759000000,
"evenity": 714000000,
"tepezza": 576000000,
"otezla": 491000000,
"enbrel": 580000000,
"blincyto": 472000000,
"nplate": 430000000,
"tezspire": 486000000,
"xgeva": 352000000,
"aranesp": 352000000,
"krystexxa": 400000000,
"kyprolis": 314000000,
"vectibix": 338000000,
"uplizna": 335000000,
"imdelltra_imdylltra": 288000000,
"other_products": 1697000000,
"total_product_sales": 9537000000
},
"product_sales_by_geography": {
"united_states": 6990000000,
"rest_of_world": 2547000000
}
},
{
"fiscal_year": 2025,
"fiscal_quarter": 2,
"label": "Q2 2025",
"period_start": "2025-04-01",
"period_end": "2025-06-30",
"period_type": "three months",
"source_accession": "0000318154-26-000126",
"cash_flow_source_accession": "0000318154-26-000124",
"income_statement": {
"product_sales": 8771000000,
"other_revenues": 408000000,
"total_revenues": 9179000000,
"cost_of_sales": 3011000000,
"research_and_development": 1744000000,
"selling_general_and_administrative": 1691000000,
"other_operating_expenses": 77000000,
"total_operating_expenses": 6523000000,
"operating_income": 2656000000,
"interest_expense_net": -694000000,
"other_income_expense_net": -394000000,
"income_before_income_taxes": 1568000000,
"provision_for_income_taxes": 136000000,
"net_income": 1432000000,
"basic_eps": 2.66,
"diluted_eps": 2.65,
"basic_shares": 538000000,
"diluted_shares": 541000000
},
"cash_flow": {
"operating_cash_flow": 2280000000,
"investing_cash_flow": -389000000,
"financing_cash_flow": -2673000000,
"capex": -369000000,
"free_cash_flow": 1911000000
},
"product_sales_by_product": {
"repatha": 696000000,
"prolia": 1122000000,
"evenity": 518000000,
"tepezza": 505000000,
"otezla": 618000000,
"enbrel": 604000000,
"blincyto": 384000000,
"nplate": 369000000,
"tezspire": 342000000,
"xgeva": 532000000,
"aranesp": 359000000,
"krystexxa": 349000000,
"kyprolis": 378000000,
"vectibix": 305000000,
"uplizna": 176000000,
"imdelltra_imdylltra": 134000000,
"other_products": 1380000000,
"total_product_sales": 8771000000
},
"product_sales_by_geography": {
"united_states": 6324000000,
"rest_of_world": 2447000000
}
}
],
"year_to_date": {
"label": "Six months ended June 30, 2026",
"period_start": "2026-01-01",
"period_end": "2026-06-30",
"period_type": "six months",
"source_accession": "0000318154-26-000126",
"income_statement": {
"product_sales": 17755000000.0,
"other_revenues": 917000000.0,
"total_revenues": 18672000000.0,
"cost_of_sales": 5555000000.0,
"research_and_development": 3587000000.0,
"selling_general_and_administrative": 3347000000.0,
"other_operating_expenses": 3000000.0,
"total_operating_expenses": 12492000000.0,
"operating_income": 6180000000.0,
"interest_expense_net": -1330000000.0,
"other_income_expense_net": 2000000.0,
"income_before_income_taxes": 4852000000.0,
"provision_for_income_taxes": 658000000.0,
"net_income": 4194000000.0,
"basic_eps": 7.77,
"diluted_eps": 7.71,
"basic_shares": 540000000.0,
"diluted_shares": 544000000.0
},
"cash_flow": {
"depreciation_amortization_and_other": 2228000000.0,
"impairment_of_intangible_assets": 0.0,
"stock_based_compensation": 240000000.0,
"operating_cash_flow": 6191000000.0,
"capex": -1225000000.0,
"investing_cash_flow": -1285000000.0,
"net_proceeds_from_issuance_of_debt": 3964000000.0,
"extinguishment_of_debt": -233000000.0,
"repayment_of_debt": -833000000.0,
"dividends_paid": -2720000000.0,
"financing_cash_flow": -46000000.0,
"free_cash_flow": 4966000000.0
},
"product_sales_by_product": {
"repatha": 1829000000.0,
"prolia": 1486000000.0,
"evenity": 1276000000.0,
"tepezza": 1066000000.0,
"otezla": 922000000.0,
"enbrel": 900000000.0,
"blincyto": 887000000.0,
"nplate": 842000000.0,
"tezspire": 829000000.0,
"xgeva": 763000000.0,
"aranesp": 663000000.0,
"krystexxa": 655000000.0,
"kyprolis": 644000000.0,
"vectibix": 625000000.0,
"uplizna": 597000000.0,
"imdelltra_imdylltra": 546000000.0,
"other_products": 3225000000.0,
"total_product_sales": 17755000000.0
},
"product_sales_by_geography": {
"united_states": 12763000000.0,
"rest_of_world": 4992000000.0
},
"prior_year_comparative": {
"label": "Six months ended June 30, 2025",
"period_start": "2025-01-01",
"period_end": "2025-06-30",
"period_type": "six months",
"source_accession": "0000318154-26-000126",
"income_statement": {
"product_sales": 16644000000.0,
"other_revenues": 684000000.0,
"total_revenues": 17328000000.0,
"cost_of_sales": 5979000000.0,
"research_and_development": 3230000000.0,
"selling_general_and_administrative": 3378000000.0,
"other_operating_expenses": 907000000.0,
"total_operating_expenses": 13494000000.0,
"operating_income": 3834000000.0,
"interest_expense_net": -1417000000.0,
"other_income_expense_net": 1124000000.0,
"income_before_income_taxes": 3541000000.0,
"provision_for_income_taxes": 379000000.0,
"net_income": 3162000000.0,
"basic_eps": 5.88,
"diluted_eps": 5.84,
"basic_shares": 538000000.0,
"diluted_shares": 541000000.0
},
"cash_flow": {
"depreciation_amortization_and_other": 2728000000.0,
"impairment_of_intangible_assets": 800000000.0,
"stock_based_compensation": 242000000.0,
"operating_cash_flow": 3671000000.0,
"capex": -780000000.0,
"investing_cash_flow": -836000000.0,
"net_proceeds_from_issuance_of_debt": 0.0,
"extinguishment_of_debt": -602000000.0,
"repayment_of_debt": -3500000000.0,
"dividends_paid": -2559000000.0,
"financing_cash_flow": -6780000000.0,
"free_cash_flow": 2891000000.0
},
"product_sales_by_product": {
"repatha": 1352000000.0,
"prolia": 2221000000.0,
"evenity": 960000000.0,
"tepezza": 886000000.0,
"otezla": 1055000000.0,
"enbrel": 1114000000.0,
"blincyto": 754000000.0,
"nplate": 682000000.0,
"tezspire": 627000000.0,
"xgeva": 1098000000.0,
"aranesp": 699000000.0,
"krystexxa": 585000000.0,
"kyprolis": 702000000.0,
"vectibix": 572000000.0,
"uplizna": 267000000.0,
"imdelltra_imdylltra": 215000000.0,
"other_products": 2855000000.0,
"total_product_sales": 16644000000.0
},
"product_sales_by_geography": {
"united_states": 11986000000.0,
"rest_of_world": 4658000000.0
},
"dividends": {
"dividends_declared": 1280000000.0,
"dividends_declared_per_share": 2.38
}
},
"dividends": {
"dividends_declared": 1362000000.0,
"dividends_declared_per_share": 2.52
}
},
"trailing_twelve_months": {
"label": "Twelve months ended June 30, 2026",
"period_start": "2025-07-01",
"period_end": "2026-06-30",
"period_type": "trailing twelve months",
"source_accession": "0000318154-26-000126",
"derived_from_accessions": [
"0000318154-26-000010",
"0000318154-26-000126"
],
"income_statement": {
"product_sales": 36259000000.0,
"other_revenues": 1836000000.0,
"total_revenues": 38095000000.0,
"cost_of_sales": 11613000000.0,
"research_and_development": 7629000000.0,
"selling_general_and_administrative": 7019000000.0,
"operating_income": 11426000000.0,
"net_income": 8743000000.0,
"diluted_eps": 16.1
},
"cash_flow": {
"operating_cash_flow": 12478000000.0,
"capex": -2303000000.0,
"free_cash_flow": 10175000000.0,
"dividends_paid": -5285000000.0
}
},
"notes": [
"Annual figures for 2025, 2024 and 2023 are taken from the FY2025 Form 10-K (accession 0000318154-26-000010). The 10-K presents three years of income statement and cash flows but only two year-end balance sheets, so FY2023 carries no balance sheet.",
"Quarterly figures for the three months ended June 30, 2026 and 2025, the six-month year-to-date figures, and the June 30, 2026 balance sheet are taken from the Q2 2026 Form 10-Q (accession 0000318154-26-000126). The 10-Q does not present a June 30, 2025 balance sheet, so Q2 2025 carries none.",
"The 10-Q's cash flow statement covers six months only. The three-month cash flow figures for Q2 2026 and Q2 2025 (operating, investing and financing cash flow, capital expenditures and free cash flow) come from the Q2 2026 earnings release furnished as Exhibit 99.1 to the Form 8-K filed August 4, 2026 (accession 0000318154-26-000124), not from the 10-Q.",
"Amgen reports one operating segment, human therapeutics, so the record is organized as a single consolidated business, with product sales broken out by product and by U.S. versus rest of world (ROW) as printed in the revenues note of each filing.",
"Free cash flow follows Amgen's own definition: net cash provided by operating activities less capital expenditures. The quarterly and six-month free cash flow figures are printed in the Q2 2026 earnings release; the six-month figures equal the 10-Q's operating cash flow less its purchases of property, plant and equipment. The annual free cash flow is computed from the 10-K's cash flow statement in the same way; the FY2025 ($8,100 million) and FY2024 ($10,394 million) results equal the figures Amgen printed in its fourth-quarter 2025 earnings release (accession 0000318154-26-000003). FY2023 ($7,359 million) equals the figure Amgen printed in its fourth-quarter 2024 earnings release (accession 0000318154-25-000005).",
"Capital expenditures are the cash flow statement's 'Purchases of property, plant and equipment' (the earnings release labels the same amount 'Capital expenditures').",
"Signs follow the filings: cash outflows and expense amounts printed in parentheses are stored as negative numbers, so interest_expense_net and capex are negative. other_income_expense_net is positive for net other income and negative for net other expense.",
"total_debt_derived is the current portion of long-term debt plus long-term debt, at their balance-sheet carrying amounts. The balance sheet prints no total-liabilities line; total_liabilities_derived is the sum of total current liabilities, long-term debt, long-term deferred tax liabilities, long-term tax liabilities and other noncurrent liabilities, and with stockholders' equity it equals total assets in every period.",
"No gross profit line is reported because Amgen does not present one. Its cost of sales includes most of the amortization of acquired intangible assets, which the 10-Q puts at $890 million for Q2 2026 and $1.1 billion for Q2 2025.",
"Shares outstanding come from the statements of stockholders' equity, which print them in millions to one decimal place. Weighted-average basic and diluted shares are printed in whole millions on the income statement.",
"Dividends declared, in total and per share, come from the statements of stockholders' equity. The six-month statements show $2.52 per share declared in 2026 and $2.38 in 2025; the three-month statements for the second quarters of 2026 and 2025 show no dividends declared, so no quarterly dividend-declared figure is given. Dividends paid in cash are in the cash flow block.",
"The 10-K names 14 principal products in its revenues note; the 10-Q names 16, adding UPLIZNA and IMDELLTRA/IMDYLLTRA, whose sales the 10-K includes in 'Other products'. 'Other products' therefore covers fewer products in the quarterly and six-month periods than in the annual periods, and the two are not comparable. TEPEZZA and KRYSTEXXA came with the acquisition of Horizon on October 6, 2023, so FY2023 includes only their post-acquisition sales.",
"The trailing-twelve-month view is derived, not printed by any filing: FY2025 from the 10-K, plus the six months ended June 30, 2026, less the six months ended June 30, 2025, both from the 10-Q. Its diluted earnings per share ($16.10) is the same arithmetic applied to the published per-share figures ($14.23 + $7.71 - $5.84), not a figure Amgen reports.",
"The 10-Q states that certain prior-period amounts were reclassified to conform with the current presentation; the 2025 comparatives here are as presented in the 10-Q.",
"No stock split, currency translation or ADR adjustment applies: Amgen reports in U.S. dollars, its common stock trades directly, and it has no stock split in the periods covered."
],
"uncertainties": [
"The trailing-twelve-month figures, including the $16.10 diluted earnings per share, are computed from the annual and six-month columns and do not appear in any filing.",
"Three-month cash flow figures for Q2 2026 rest on the Q2 2026 earnings release alone, because the 10-Q prints only six-month cash flows. The Q2 2025 three-month figures are also printed in Amgen's Q2 2025 earnings release (accession 0000318154-25-000054)."
],
"headline": {
"period": "Q2 FY2026",
"period_end_words": "June 30, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 10054000000,
"text": "$10.05 billion",
"exact": "$10,054,000,000",
"compact": "$10.05B",
"abs": "$10.05 billion",
"prior_value": 9179000000,
"prior": "$9.18 billion",
"priorabs": "$9.18 billion",
"yoy": "up 9.5%",
"source": {
"array": "quarterly",
"field": "income_statement.total_revenues",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000318154-26-000126",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000318154-26-000126",
"gap_days": 365
}
},
{
"label": "Net income",
"format": "usd",
"value": 2375000000,
"text": "$2.38 billion",
"exact": "$2,375,000,000",
"compact": "$2.38B",
"abs": "$2.38 billion",
"prior_value": 1432000000,
"prior": "$1.43 billion",
"priorabs": "$1.43 billion",
"yoy": "up 65.9%",
"source": {
"array": "quarterly",
"field": "income_statement.net_income",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000318154-26-000126",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000318154-26-000126",
"gap_days": 365
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": 4.37,
"text": "$4.37",
"exact": "$4.37",
"compact": "$4.37",
"abs": "$4.37",
"prior_value": 2.65,
"prior": "$2.65",
"priorabs": "$2.65",
"yoy": "up 64.9%",
"source": {
"array": "quarterly",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000318154-26-000126",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000318154-26-000126",
"gap_days": 365
}
},
{
"label": "Operating income",
"format": "usd",
"value": 3514000000,
"text": "$3.51 billion",
"exact": "$3,514,000,000",
"compact": "$3.51B",
"abs": "$3.51 billion",
"prior_value": 2656000000,
"prior": "$2.66 billion",
"priorabs": "$2.66 billion",
"yoy": "up 32.3%",
"source": {
"array": "quarterly",
"field": "income_statement.operating_income",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000318154-26-000126",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000318154-26-000126",
"gap_days": 365
}
}
],
"summary": "Amgen reported total revenues of $10.05 billion for Q2 FY2026, the quarter ended June 30, 2026, up 9.5% from a year earlier, as volume growth in products including Repatha, EVENITY and UPLIZNA outweighed biosimilar erosion of Prolia and XGEVA. Net income was $2.38 billion, up 65.9%, and diluted earnings per share were $4.37, up 64.9%. Operating income rose to $3.51 billion, up 32.3%, as lower amortization of acquired intangible assets and smaller Horizon inventory step-up charges reduced cost of sales, and a smaller unrealized loss on Amgen's stake in BeOne Medicines added to the gain in net income.",
"qa": [
{
"q": "How much revenue did Amgen report in Q2 FY2026?",
"a": "Amgen reported total revenues of $10.05 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 9.5% from $9.18 billion in the same quarter a year earlier."
},
{
"q": "What was Amgen's net income in Q2 FY2026?",
"a": "Amgen's net income was $2.38 billion in Q2 FY2026, the quarter ended June 30, 2026, up 65.9% from $1.43 billion in the same quarter a year earlier."
},
{
"q": "What were Amgen's earnings per share in Q2 FY2026?",
"a": "Amgen earned $4.37 per diluted share in Q2 FY2026, the quarter ended June 30, 2026, up 64.9% from $2.65 in the same quarter a year earlier."
},
{
"q": "Why did Amgen's profit grow faster than its revenue in Q2 FY2026?",
"a": "Amgen's operating income rose to $3.51 billion in Q2 FY2026, up 32.3% from $2.66 billion a year earlier, because revenue grew while lower amortization of acquired intangible assets and smaller Horizon inventory step-up charges reduced cost of sales. Net income also benefited from a smaller unrealized loss on Amgen's stake in BeOne Medicines than in the same quarter a year earlier."
}
]
},
"company_details": {
"Name": "Amgen Inc",
"Ticker": "AMGN",
"CIK": "0000318154",
"Exchange": "Nasdaq",
"State": "California",
"Incorporation": "Delaware",
"SIC": "2836",
"Office": "Life Sciences",
"Industry": "Biological Products, (No Diagnostic Substances)"
},
"next_filing": {
"predicted_date": "2026-11-04",
"predicted_type": "10-Q"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "Q2",
"tag": "FY26Q2",
"period_end": "2026-06-30",
"form": "10-Q",
"accession": "0000318154-26-000126",
"fiscal_year_end": "1231",
"source": "facts"
},
"source_filings": [
{
"role": "annual",
"current": false,
"form": "10-K",
"fiscal_year": 2025,
"fiscal_period": "FY",
"tag": "FY25",
"period_end": "2025-12-31",
"filed": "2026-02-13",
"accession": "0000318154-26-000010",
"url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm",
"source": "reported"
},
{
"role": "quarterly",
"current": true,
"form": "10-Q",
"fiscal_year": 2026,
"fiscal_period": "Q2",
"tag": "FY26Q2",
"period_end": "2026-06-30",
"filed": "2026-08-05",
"accession": "0000318154-26-000126",
"url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm",
"source": "facts"
}
],
"figure_sources": {
"about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '<document>#<anchor>', and the link is documents[<document>] + '#<anchor>': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.",
"documents": {
"d1": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm",
"d2": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm"
},
"annual": [
{
"period_end": "2025-12-31",
"income_statement": {
"product_sales": "d1#f-64",
"other_revenues": "d1#f-67",
"total_revenues": "d1#f-70",
"cost_of_sales": "d1#f-73",
"research_and_development": "d1#f-76",
"selling_general_and_administrative": "d1#f-79",
"other_operating_expenses": "d1#f-82",
"total_operating_expenses": "d1#f-85",
"operating_income": "d1#f-88",
"interest_expense_net": "d1#f-91",
"other_income_expense_net": "d1#f-94",
"income_before_income_taxes": "d1#f-97",
"provision_for_income_taxes": "d1#f-100",
"net_income": "d1#f-103",
"basic_eps": "d1#f-106",
"diluted_eps": "d1#f-109",
"basic_shares": "d1#f-112",
"diluted_shares": "d1#f-115"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d1#f-136",
"trade_receivables_net": "d1#f-138",
"inventories": "d1#f-140",
"other_current_assets": "d1#f-142",
"total_current_assets": "d1#f-144",
"property_plant_and_equipment_net": "d1#f-146",
"intangible_assets_net": "d1#f-148",
"goodwill": "d1#f-150",
"other_noncurrent_assets": "d1#f-152",
"total_assets": "d1#f-154",
"accounts_payable": "d1#f-156",
"accrued_liabilities": "d1#f-158",
"current_portion_of_long_term_debt": "d1#f-160",
"total_current_liabilities": "d1#f-162",
"long_term_debt": "d1#f-164",
"long_term_deferred_tax_liabilities": "d1#f-166",
"long_term_tax_liabilities": "d1#f-168",
"other_noncurrent_liabilities": "d1#f-170",
"common_stock_and_additional_paid_in_capital": "d1#f-182",
"accumulated_deficit": "d1#f-184",
"accumulated_other_comprehensive_loss": "d1#f-186",
"total_stockholders_equity": "d1#f-188",
"total_liabilities_and_stockholders_equity": "d1#f-190",
"shares_outstanding": "d1#f-180",
"total_debt_derived": "d1#f-1496"
},
"cash_flow": {
"depreciation_amortization_and_other": "d1#f-262",
"impairment_of_intangible_assets": "d1#f-265",
"stock_based_compensation": "d1#f-268",
"operating_cash_flow": "d1#f-307",
"cash_paid_for_acquisitions": "d1#f-310",
"capex": "d1#f-319",
"investing_cash_flow": "d1#f-325",
"extinguishment_of_debt": "d1#f-1584",
"repayment_of_debt": "d1#f-334",
"dividends_paid": "d1#f-340",
"financing_cash_flow": "d1#f-346"
},
"product_sales_by_product": {
"prolia": "d1#f-455",
"repatha": "d1#f-464",
"otezla": "d1#f-473",
"enbrel": "d1#f-482",
"evenity": "d1#f-491",
"xgeva": "d1#f-500",
"tepezza": "d1#f-509",
"blincyto": "d1#f-518",
"nplate": "d1#f-527",
"tezspire": "d1#f-536",
"kyprolis": "d1#f-545",
"aranesp": "d1#f-554",
"krystexxa": "d1#f-563",
"vectibix": "d1#f-572",
"other_products": "d1#f-581",
"total_product_sales": "d1#f-590"
},
"product_sales_by_geography": {
"united_states": "d1#f-588",
"rest_of_world": "d1#f-589"
},
"dividends": {
"dividends_declared": "d1#f-246",
"dividends_declared_per_share": "d1#f-244"
}
},
{
"period_end": "2024-12-31",
"income_statement": {
"product_sales": "d1#f-65",
"other_revenues": "d1#f-68",
"total_revenues": "d1#f-71",
"cost_of_sales": "d1#f-74",
"research_and_development": "d1#f-77",
"selling_general_and_administrative": "d1#f-80",
"other_operating_expenses": "d1#f-83",
"total_operating_expenses": "d1#f-86",
"operating_income": "d1#f-89",
"interest_expense_net": "d1#f-92",
"other_income_expense_net": "d1#f-95",
"income_before_income_taxes": "d1#f-98",
"provision_for_income_taxes": "d1#f-101",
"net_income": "d1#f-104",
"basic_eps": "d1#f-107",
"diluted_eps": "d1#f-110",
"basic_shares": "d1#f-113",
"diluted_shares": "d1#f-116"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d1#f-137",
"trade_receivables_net": "d1#f-139",
"inventories": "d1#f-141",
"other_current_assets": "d1#f-143",
"total_current_assets": "d1#f-145",
"property_plant_and_equipment_net": "d1#f-147",
"intangible_assets_net": "d1#f-149",
"goodwill": "d1#f-151",
"other_noncurrent_assets": "d1#f-153",
"total_assets": "d1#f-155",
"accounts_payable": "d1#f-157",
"accrued_liabilities": "d1#f-159",
"current_portion_of_long_term_debt": "d1#f-161",
"total_current_liabilities": "d1#f-163",
"long_term_debt": "d1#f-165",
"long_term_deferred_tax_liabilities": "d1#f-167",
"long_term_tax_liabilities": "d1#f-171",
"other_noncurrent_liabilities": "d1#f-171",
"common_stock_and_additional_paid_in_capital": "d1#f-183",
"accumulated_deficit": "d1#f-185",
"accumulated_other_comprehensive_loss": "d1#f-187",
"total_stockholders_equity": "d1#f-189",
"total_liabilities_and_stockholders_equity": "d1#f-191",
"shares_outstanding": "d1#f-181",
"total_debt_derived": "d1#f-1497"
},
"cash_flow": {
"depreciation_amortization_and_other": "d1#f-263",
"impairment_of_intangible_assets": "d1#f-266",
"stock_based_compensation": "d1#f-269",
"operating_cash_flow": "d1#f-308",
"capex": "d1#f-320",
"investing_cash_flow": "d1#f-326",
"extinguishment_of_debt": "d1#f-1593",
"repayment_of_debt": "d1#f-335",
"repurchases_of_common_stock": "d1#f-338",
"dividends_paid": "d1#f-341",
"financing_cash_flow": "d1#f-347"
},
"product_sales_by_product": {
"prolia": "d1#f-458",
"repatha": "d1#f-467",
"otezla": "d1#f-476",
"enbrel": "d1#f-485",
"evenity": "d1#f-494",
"xgeva": "d1#f-503",
"tepezza": "d1#f-512",
"blincyto": "d1#f-521",
"nplate": "d1#f-530",
"tezspire": "d1#f-539",
"kyprolis": "d1#f-548",
"aranesp": "d1#f-557",
"krystexxa": "d1#f-566",
"vectibix": "d1#f-575",
"other_products": "d1#f-584",
"total_product_sales": "d1#f-593"
},
"product_sales_by_geography": {
"united_states": "d1#f-591",
"rest_of_world": "d1#f-592"
},
"dividends": {
"dividends_declared": "d1#f-224",
"dividends_declared_per_share": "d1#f-222"
}
},
{
"period_end": "2023-12-31",
"income_statement": {
"product_sales": "d1#f-66",
"other_revenues": "d1#f-69",
"total_revenues": "d1#f-72",
"cost_of_sales": "d1#f-75",
"research_and_development": "d1#f-78",
"selling_general_and_administrative": "d1#f-81",
"other_operating_expenses": "d1#f-84",
"total_operating_expenses": "d1#f-87",
"operating_income": "d1#f-90",
"interest_expense_net": "d1#f-93",
"other_income_expense_net": "d1#f-96",
"income_before_income_taxes": "d1#f-99",
"provision_for_income_taxes": "d1#f-102",
"net_income": "d1#f-105",
"basic_eps": "d1#f-108",
"diluted_eps": "d1#f-111",
"basic_shares": "d1#f-114",
"diluted_shares": "d1#f-117"
},
"cash_flow": {
"depreciation_amortization_and_other": "d1#f-264",
"impairment_of_intangible_assets": "d1#f-267",
"stock_based_compensation": "d1#f-270",
"operating_cash_flow": "d1#f-309",
"cash_paid_for_acquisitions": "d1#f-312",
"capex": "d1#f-321",
"investing_cash_flow": "d1#f-327",
"net_proceeds_from_issuance_of_debt": "d1#f-330",
"extinguishment_of_debt": "d1#f-1603",
"repayment_of_debt": "d1#f-336",
"dividends_paid": "d1#f-342",
"financing_cash_flow": "d1#f-348"
},
"product_sales_by_product": {
"prolia": "d1#f-461",
"repatha": "d1#f-470",
"otezla": "d1#f-479",
"enbrel": "d1#f-488",
"evenity": "d1#f-497",
"xgeva": "d1#f-506",
"tepezza": "d1#f-515",
"blincyto": "d1#f-524",
"nplate": "d1#f-533",
"tezspire": "d1#f-542",
"kyprolis": "d1#f-551",
"aranesp": "d1#f-560",
"krystexxa": "d1#f-569",
"vectibix": "d1#f-578",
"other_products": "d1#f-587",
"total_product_sales": "d1#f-596"
},
"product_sales_by_geography": {
"united_states": "d1#f-594",
"rest_of_world": "d1#f-595"
},
"dividends": {
"dividends_declared": "d1#f-203",
"dividends_declared_per_share": "d1#f-201"
}
}
],
"quarterly": [
{
"period_end": "2026-06-30",
"income_statement": {
"product_sales": "d2#f-30",
"other_revenues": "d2#f-34",
"total_revenues": "d2#f-38",
"cost_of_sales": "d2#f-42",
"research_and_development": "d2#f-46",
"selling_general_and_administrative": "d2#f-50",
"other_operating_expenses": "d2#f-54",
"total_operating_expenses": "d2#f-58",
"operating_income": "d2#f-62",
"interest_expense_net": "d2#f-66",
"other_income_expense_net": "d2#f-70",
"income_before_income_taxes": "d2#f-74",
"provision_for_income_taxes": "d2#f-78",
"net_income": "d2#f-82",
"basic_eps": "d2#f-86",
"diluted_eps": "d2#f-90",
"basic_shares": "d2#f-94",
"diluted_shares": "d2#f-98"
},
"balance_sheet": {
"cash_and_cash_equivalents": "d2#f-126",
"trade_receivables_net": "d2#f-128",
"inventories": "d2#f-130",
"other_current_assets": "d2#f-132",
"total_current_assets": "d2#f-134",
"property_plant_and_equipment_net": "d2#f-136",
"intangible_assets_net": "d2#f-138",
"goodwill": "d2#f-140",
"other_noncurrent_assets": "d2#f-142",
"total_assets": "d2#f-144",
"accounts_payable": "d2#f-146",
"accrued_liabilities": "d2#f-148",
"current_portion_of_long_term_debt": "d2#f-150",
"total_current_liabilities": "d2#f-152",
"long_term_debt": "d2#f-154",
"long_term_deferred_tax_liabilities": "d2#f-156",
"long_term_tax_liabilities": "d2#f-158",
"other_noncurrent_liabilities": "d2#f-160",
"common_stock_and_additional_paid_in_capital": "d2#f-172",
"accumulated_deficit": "d2#f-174",
"accumulated_other_comprehensive_loss": "d2#f-176",
"total_stockholders_equity": "d2#f-178",
"total_liabilities_and_stockholders_equity": "d2#f-180",
"shares_outstanding": "d2#f-170",
"total_debt_derived": "d2#f-1036"
},
"product_sales_by_product": {
"repatha": "d2#f-423",
"prolia": "d2#f-429",
"evenity": "d2#f-435",
"tepezza": "d2#f-441",
"otezla": "d2#f-447",
"enbrel": "d2#f-453",
"blincyto": "d2#f-459",
"nplate": "d2#f-465",
"tezspire": "d2#f-471",
"xgeva": "d2#f-477",
"aranesp": "d2#f-483",
"krystexxa": "d2#f-489",
"kyprolis": "d2#f-495",
"vectibix": "d2#f-501",
"uplizna": "d2#f-507",
"imdelltra_imdylltra": "d2#f-513",
"other_products": "d2#f-519",
"total_product_sales": "d2#f-525"
},
"product_sales_by_geography": {
"united_states": "d2#f-523",
"rest_of_world": "d2#f-524"
}
},
{
"period_end": "2025-06-30",
"income_statement": {
"product_sales": "d2#f-31",
"other_revenues": "d2#f-35",
"total_revenues": "d2#f-39",
"cost_of_sales": "d2#f-43",
"research_and_development": "d2#f-47",
"selling_general_and_administrative": "d2#f-51",
"other_operating_expenses": "d2#f-55",
"total_operating_expenses": "d2#f-59",
"operating_income": "d2#f-63",
"interest_expense_net": "d2#f-67",
"other_income_expense_net": "d2#f-71",
"income_before_income_taxes": "d2#f-75",
"provision_for_income_taxes": "d2#f-79",
"net_income": "d2#f-83",
"basic_eps": "d2#f-87",
"diluted_eps": "d2#f-91",
"basic_shares": "d2#f-95",
"diluted_shares": "d2#f-99"
},
"cash_flow": {
"capex": "d2#f-468"
},
"product_sales_by_product": {
"repatha": "d2#f-426",
"prolia": "d2#f-432",
"evenity": "d2#f-438",
"tepezza": "d2#f-444",
"otezla": "d2#f-450",
"enbrel": "d2#f-456",
"blincyto": "d2#f-462",
"nplate": "d2#f-468",
"tezspire": "d2#f-474",
"xgeva": "d2#f-480",
"aranesp": "d2#f-486",
"krystexxa": "d2#f-492",
"kyprolis": "d2#f-498",
"vectibix": "d2#f-504",
"uplizna": "d2#f-510",
"imdelltra_imdylltra": "d2#f-516",
"other_products": "d2#f-522",
"total_product_sales": "d2#f-528"
},
"product_sales_by_geography": {
"united_states": "d2#f-526",
"rest_of_world": "d2#f-527"
}
}
]
}
}